(NASDAQ:SMMT) MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, HARMONi, presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona, Spain. The call will be held on Monday, September 8, 2025, at 8:00am ET and will be accessible through our website, w
Related Questions
How will the ivonescimab Phase III data presented at WCLC impact Summit Therapeutics' revenue outlook and valuation?
What short‑term trading catalysts might arise from the September 8 update call, and how could they affect stock liquidity and price volatility?
How does ivonescimab's efficacy and safety profile compare to competing lung‑cancer therapies, and could it influence market share, partnership prospects, or competitive positioning?